Fulvestrant Reddy: Uses, Dosage & Side Effects
A selective estrogen receptor degrader (SERD) for the treatment of hormone receptor-positive locally advanced or metastatic breast cancer
Fulvestrant Reddy is a prescription injectable medication containing fulvestrant, a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer. Unlike selective estrogen receptor modulators (SERMs) such as tamoxifen, fulvestrant completely blocks and degrades the estrogen receptor, leaving no residual estrogen agonist activity. It is administered as an intramuscular injection (500 mg total dose given as two 250 mg injections) on a monthly schedule after an initial loading period. Fulvestrant Reddy is a biosimilar/generic version of the originator product Faslodex, offering the same clinical efficacy and safety profile. It is frequently combined with CDK4/6 inhibitors such as palbociclib, ribociclib, or abemaciclib to significantly improve outcomes in advanced HR+ breast cancer.
Quick Facts: Fulvestrant Reddy
Key Takeaways
- Fulvestrant Reddy is a selective estrogen receptor degrader (SERD) that completely blocks and degrades estrogen receptors, with no residual estrogen agonist activity – making it effective even after resistance to tamoxifen or aromatase inhibitors.
- It is indicated for hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer in postmenopausal women, or in premenopausal women when combined with ovarian suppression.
- The standard dose is 500 mg administered as two intramuscular injections (one in each buttock) on days 1, 15, 29, and then once monthly – the loading dose schedule achieves therapeutic levels more rapidly.
- Fulvestrant is frequently combined with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), with landmark trials demonstrating significant improvements in progression-free and overall survival compared to fulvestrant alone.
- The most common side effects are injection site reactions, nausea, musculoskeletal pain, fatigue, and hot flushes; serious but uncommon effects include thromboembolic events and hepatobiliary disorders.
What Is Fulvestrant Reddy and What Is It Used For?
Fulvestrant Reddy is a prescription medication that contains the active substance fulvestrant, a 7-alpha-alkylsulfinyl analogue of 17-beta-estradiol. Fulvestrant belongs to a class of drugs known as selective estrogen receptor degraders (SERDs), which represent a fundamentally different approach to estrogen receptor (ER) blockade compared to older endocrine therapies. While selective estrogen receptor modulators (SERMs) like tamoxifen compete with estradiol for binding to the estrogen receptor and exhibit tissue-dependent agonist/antagonist activity, fulvestrant binds to the ER with an affinity comparable to estradiol but acts as a pure antagonist with absolutely no agonist effects in any tissue.
The mechanism of action of fulvestrant is unique and multifaceted. Upon binding to the estrogen receptor, fulvestrant induces a conformational change that prevents receptor dimerization, which is an essential step for normal ER function. This conformational disruption blocks the receptor's ability to localize to the cell nucleus, inhibits DNA binding, and abolishes transcriptional activity. Most importantly, fulvestrant promotes rapid degradation of the ER protein through the ubiquitin-proteasome pathway, physically removing ER molecules from the cell. This triple mechanism – blocking, inactivating, and degrading the ER – results in a dramatic reduction in ER protein levels in breast cancer tissue, typically by 80–90% as demonstrated in presurgical studies. This comprehensive receptor elimination distinguishes fulvestrant from all other endocrine therapies and explains its efficacy in patients who have progressed on prior anti-estrogen treatments.
Fulvestrant Reddy is a generic version of fulvestrant manufactured by Dr. Reddy's Laboratories. It contains the same active substance at the same concentration and has been demonstrated through rigorous bioequivalence studies to provide equivalent pharmacokinetic exposure and therapeutic outcomes as the reference product Faslodex (originally developed by AstraZeneca). The availability of generic fulvestrant products such as Fulvestrant Reddy improves patient access to this important treatment by offering a more cost-effective alternative while maintaining identical clinical efficacy and safety standards.
The primary indication for Fulvestrant Reddy is the treatment of estrogen receptor-positive (ER+), locally advanced or metastatic breast cancer in postmenopausal women. Specifically, it is used in patients who have not been previously treated with endocrine therapy (as first-line treatment, typically in combination with a CDK4/6 inhibitor), or in patients whose disease has progressed on or after prior anti-estrogen therapy (such as tamoxifen or aromatase inhibitors). The efficacy of fulvestrant 500 mg as monotherapy was established in the CONFIRM trial, which demonstrated a statistically significant improvement in progression-free survival (PFS) compared to the previously used 250 mg dose (median PFS: 6.5 months vs. 5.5 months; HR 0.80, 95% CI 0.68–0.94; p = 0.006).
In the modern treatment landscape, fulvestrant is most frequently used in combination with CDK4/6 inhibitors. The rationale for this combination stems from the understanding that cyclin-dependent kinases 4 and 6 play a critical role in cell cycle progression downstream of estrogen receptor signaling. By simultaneously targeting the ER (with fulvestrant) and the cell cycle machinery (with a CDK4/6 inhibitor), the combination achieves synergistic anti-tumor activity. Three landmark phase III clinical trials have established the superiority of this approach:
- PALOMA-3 (Fulvestrant + Palbociclib): This trial enrolled 521 patients with HR+/HER2– advanced breast cancer that had progressed on prior endocrine therapy. The combination of fulvestrant plus palbociclib significantly improved median PFS compared to fulvestrant plus placebo (9.5 months vs. 4.6 months; HR 0.46, p < 0.0001). Updated overall survival analysis showed a clinically meaningful improvement of 6.9 months (34.9 vs. 28.0 months).
- MONALEESA-3 (Fulvestrant + Ribociclib): In 726 postmenopausal patients with HR+/HER2– advanced breast cancer (including first-line and second-line settings), the combination of fulvestrant plus ribociclib demonstrated a significant improvement in PFS (20.5 months vs. 12.8 months; HR 0.59, p < 0.001 in the overall population). Overall survival was also significantly improved (not reached vs. 40.0 months; HR 0.72, p = 0.00455).
- MONARCH-2 (Fulvestrant + Abemaciclib): This trial included 669 patients with HR+/HER2– advanced breast cancer that had progressed on prior endocrine therapy. Adding abemaciclib to fulvestrant significantly improved median PFS (16.4 months vs. 9.3 months; HR 0.55, p < 0.001) and demonstrated a statistically significant improvement in overall survival (46.7 months vs. 37.3 months; HR 0.757, p = 0.0137).
Fulvestrant occupies a central role in the management of HR+/HER2– advanced breast cancer. International guidelines from ESMO, ASCO, and NCCN recommend fulvestrant-based combinations (particularly with CDK4/6 inhibitors) as standard-of-care treatment options for both first-line and subsequent-line therapy. The choice between fulvestrant-based regimens and aromatase inhibitor-based regimens depends on prior treatment history, disease burden, menopausal status, and individual patient factors.
What Should You Know Before Taking Fulvestrant Reddy?
Contraindications
Fulvestrant Reddy must not be used in patients with a known hypersensitivity to the active substance fulvestrant or to any of the excipients in the formulation. The pre-filled syringe contains excipients including ethanol (96%), benzyl alcohol, benzyl benzoate, and castor oil. Patients with known allergies to any of these components should not receive this medication. Hypersensitivity reactions, including urticaria and angioedema, have been reported in post-marketing experience with fulvestrant products.
Fulvestrant is contraindicated in pregnancy. Animal studies have shown reproductive toxicity, and the pharmacological action of fulvestrant (estrogen receptor antagonism) is expected to cause harm to the developing fetus. Women of childbearing potential must use effective contraception during treatment and for two years after the last dose. A pregnancy test should be performed before initiating therapy to confirm that the patient is not pregnant.
- You are allergic to fulvestrant or any ingredient in the formulation
- You are pregnant or think you may be pregnant
- You are breastfeeding (fulvestrant is excreted in breast milk in animal studies)
- You have severe hepatic impairment (Child-Pugh class C) – not studied, not recommended
Warnings and Precautions
Fulvestrant should be used with caution in patients with moderate hepatic impairment (Child-Pugh class B). In these patients, fulvestrant exposure may be increased approximately 2.5-fold due to reduced hepatic clearance. The EMA SmPC recommends a dose reduction to 250 mg in patients with moderate hepatic impairment, while the FDA label advises a similar dose adjustment. Liver function should be monitored periodically during treatment. Fulvestrant has not been studied in patients with severe hepatic impairment (Child-Pugh class C) and its use is therefore not recommended in this population.
Because fulvestrant is administered as an intramuscular injection, particular caution is required in patients receiving anticoagulant therapy or in those with bleeding diatheses or thrombocytopenia. The intramuscular injection route carries an inherent risk of bleeding or hematoma at the injection site, which may be exacerbated in anticoagulated patients. The injection should be given slowly and the injection site monitored for any signs of excessive bleeding. For patients on anticoagulants, it is advisable to schedule the fulvestrant injection at a time when the anticoagulant effect is at its lowest (for example, at the trough of warfarin's effect).
Thromboembolic events have been observed in patients receiving fulvestrant in clinical trials, although a causal relationship has not been definitively established. Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, has been reported. Patients should be advised to seek immediate medical attention if they develop signs or symptoms suggestive of VTE, such as leg swelling, pain, warmth, or sudden shortness of breath and chest pain.
Fulvestrant may affect bone mineral density over time, given its anti-estrogenic mechanism. However, data on long-term skeletal effects are limited. Patients at high risk for osteoporosis should have bone health assessed and monitored during treatment. Supplementation with calcium and vitamin D may be advisable, and consideration should be given to bone-protective agents in patients with established osteoporosis or significant risk factors.
Pregnancy and Breastfeeding
Fulvestrant is contraindicated during pregnancy. It is classified as a Category D drug (evidence of human fetal risk) by the FDA. In animal studies, fulvestrant at doses lower than the clinical dose caused decreased fertility, increased fetal loss, and delivery dystocia. Given the pharmacological mechanism of the drug (complete estrogen receptor antagonism), adverse effects on the developing fetus are expected. Women of childbearing potential must use effective non-hormonal contraception during treatment and for two years after the last dose, reflecting the drug's long elimination half-life. If pregnancy occurs during treatment, the patient should be informed of the potential hazard to the fetus.
It is not known whether fulvestrant is excreted in human breast milk, although it has been detected in the milk of lactating rats. Given the potential for serious adverse effects in nursing infants from fulvestrant's anti-estrogenic activity, breastfeeding should be discontinued during treatment and for two years after the final dose.
Fulvestrant may impair fertility in women of childbearing potential based on its pharmacological mechanism. The effects on fertility are expected to be reversible upon discontinuation, although recovery time may be prolonged due to the drug's long half-life. Discuss fertility preservation options with your oncologist before starting treatment if future pregnancy is desired.
How Does Fulvestrant Reddy Interact with Other Drugs?
Fulvestrant is metabolized primarily by cytochrome P450 3A4 (CYP3A4), with additional involvement of multiple other metabolic pathways including sulfation and glucuronidation. Despite CYP3A4 involvement, formal interaction studies with ketoconazole (a potent CYP3A4 inhibitor) and rifampicin (a potent CYP3A4 inducer) have shown no clinically significant changes in fulvestrant pharmacokinetics. This is likely because fulvestrant's absorption from the intramuscular depot site is the rate-limiting step in its pharmacokinetics, rather than hepatic metabolism. As such, even substantial changes in metabolic clearance have minimal impact on overall drug exposure.
Similarly, in vitro studies have shown that fulvestrant does not significantly inhibit any of the major CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at clinically relevant concentrations. This means that fulvestrant is unlikely to affect the metabolism or plasma levels of other drugs that are substrates of these enzymes. This favorable interaction profile is an important clinical advantage, particularly in breast cancer patients who frequently take multiple concomitant medications.
When fulvestrant is used in combination with CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib), no pharmacokinetic interactions requiring dose adjustment of either drug have been identified. The combination is based on pharmacodynamic synergy rather than pharmacokinetic interaction, and the approved doses of both agents can be used without modification. Specific interaction considerations for each CDK4/6 inhibitor (which have their own CYP3A4-related interactions) should be reviewed in the prescribing information for those individual drugs.
Major Interactions
| Drug / Class | Interaction | Clinical Recommendation |
|---|---|---|
| Warfarin / Oral anticoagulants | Increased bleeding risk at IM injection site; theoretical pharmacodynamic interaction | Monitor INR closely; schedule injection at anticoagulant trough; apply pressure post-injection |
| Estrogen-containing therapies (HRT, oral contraceptives) | Pharmacological antagonism; estrogen would counteract fulvestrant's anti-estrogenic effect | Do not use concurrently; discontinue any estrogen therapy before starting fulvestrant |
| Tamoxifen | Competitive binding at estrogen receptor; tamoxifen may reduce fulvestrant efficacy by occupying ER | Not recommended in combination; use sequentially, not concurrently |
Minor Interactions
| Drug / Class | Interaction | Clinical Recommendation |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole) | Theoretical increase in fulvestrant exposure; not clinically significant in formal studies | No dose adjustment required; monitor for increased side effects |
| Strong CYP3A4 inducers (rifampicin, phenytoin) | Theoretical decrease in fulvestrant exposure; not clinically significant in formal studies | No dose adjustment required; clinical significance unlikely due to rate-limited absorption |
| CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) | No pharmacokinetic interaction; pharmacodynamic synergy (intended combination) | No dose adjustment of fulvestrant required; use standard doses of both agents |
| Bisphosphonates / Denosumab | No pharmacokinetic interaction; commonly co-administered for bone protection | Safe to use concurrently; recommended for bone health management |
Although fulvestrant itself has minimal drug interaction potential, the CDK4/6 inhibitors used in combination have significant CYP3A4-related interactions. When prescribing fulvestrant-based combination therapy, ensure that the interaction profile of the CDK4/6 inhibitor component is carefully reviewed, particularly regarding concomitant use of strong CYP3A4 inhibitors or inducers, which may require dose adjustment of the CDK4/6 inhibitor (not fulvestrant).
What Is the Correct Dosage of Fulvestrant Reddy?
Adults
Standard Adult Dosage
The recommended dose of fulvestrant is 500 mg administered intramuscularly once monthly, with an additional 500 mg dose given on day 15 of the first month of treatment (loading dose regimen). This means the patient receives injections on Day 1, Day 15, Day 29, and then every 28 (±3) days thereafter. Each 500 mg dose is given as two 250 mg/5 mL injections, one into each buttock (gluteal muscle), administered slowly over 1–2 minutes per injection using the supplied pre-filled syringes with safety needles.
The loading dose regimen (days 1, 15, 29) was established based on pharmacokinetic modeling and was validated in the CONFIRM trial, which demonstrated superior efficacy of the 500 mg dose compared to 250 mg. The loading doses ensure that steady-state plasma concentrations are reached more rapidly, typically within the first month rather than after 3–6 months as would occur with monthly dosing alone. This earlier achievement of therapeutic drug levels translates to faster onset of clinical activity, which is particularly important in patients with progressive disease.
The injection must be administered by a trained healthcare professional. The intramuscular route targets the gluteal muscle, which provides a large injection depot for the slowly absorbed formulation. The injection should be given slowly (1–2 minutes per syringe) to minimize injection site discomfort. The pre-filled syringes should be allowed to reach room temperature (approximately 15–30 minutes out of the refrigerator) before administration. The needle safety device should be activated after injection to prevent needlestick injuries.
| Patient Group | Dose | Schedule | Notes |
|---|---|---|---|
| Adults (postmenopausal women) | 500 mg (2 × 250 mg IM) | Days 1, 15, 29, then monthly | Standard approved regimen |
| Adults (premenopausal women) | 500 mg (2 × 250 mg IM) | Days 1, 15, 29, then monthly | Must combine with LHRH agonist for ovarian suppression |
| Moderate hepatic impairment (Child-Pugh B) | 250 mg (1 × 250 mg IM) | Days 1, 15, 29, then monthly | Dose reduction due to increased exposure |
| Mild hepatic impairment (Child-Pugh A) | 500 mg (2 × 250 mg IM) | Days 1, 15, 29, then monthly | No dose adjustment required |
| Renal impairment | 500 mg (2 × 250 mg IM) | Days 1, 15, 29, then monthly | No dose adjustment required (CrCl ≥ 30 mL/min) |
Children
Fulvestrant Reddy is not indicated for use in children or adolescents. The safety and efficacy of fulvestrant in pediatric patients have not been established. Hormone receptor-positive breast cancer is exceedingly rare in the pediatric population, and there are no clinical data to support the use of fulvestrant in patients under 18 years of age.
Elderly
No dose adjustment is required in elderly patients. Clinical trials of fulvestrant included a substantial proportion of patients aged 65 years and older, and no overall differences in safety or efficacy were observed between elderly patients and younger adults. Fulvestrant has been studied in patients up to 89 years of age. Standard age-appropriate monitoring of hepatic and renal function is recommended, as is assessment of general performance status and comorbidities that may influence treatment decisions.
Missed Dose
If a scheduled dose of Fulvestrant Reddy is missed, the injection should be administered as soon as possible. There is no need to adjust the subsequent dosing schedule; the next dose should be given at the originally planned time (approximately 28 days after the missed dose is given). If a dose is delayed by more than a few days, contact your oncologist for guidance. Because fulvestrant has a long elimination half-life (approximately 40 days), brief delays in dosing are unlikely to result in a significant drop below therapeutic drug levels, although maintaining the regular schedule is important for optimal disease control.
Overdose
There is no clinical experience with fulvestrant overdose in humans. In animal studies, no additional effects beyond those attributable to the anti-estrogenic pharmacology of fulvestrant were observed at doses many times the recommended human dose. There is no specific antidote for fulvestrant overdose. In case of overdose, treatment should be symptomatic and supportive. Given the intramuscular depot formulation, accidental overdose with fulvestrant is unlikely in the clinical setting. If overdose is suspected, the patient should be monitored and managed with appropriate supportive care under medical supervision.
What Are the Side Effects of Fulvestrant Reddy?
The safety profile of fulvestrant has been extensively characterized through clinical trials involving thousands of patients and through post-marketing surveillance since its initial approval in 2002. Overall, fulvestrant is well-tolerated, with most adverse effects being mild to moderate in severity (Grade 1–2). The incidence and types of side effects observed with Fulvestrant Reddy are expected to be identical to those of the reference product, given bioequivalent drug exposure.
The frequency of adverse reactions reported in clinical trials is categorized below using the standard frequency classification: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and rare (<1/1,000). The data below are derived primarily from the CONFIRM trial (fulvestrant 500 mg monotherapy) and the FALCON trial (fulvestrant 500 mg as first-line monotherapy), supplemented by data from combination trials with CDK4/6 inhibitors.
Very Common
- Nausea (reported in 20–30% of patients)
- Injection site reactions (pain, inflammation, swelling, or induration at the gluteal injection site; up to 27%)
- Fatigue and asthenia (tiredness and weakness; 15–25%)
- Musculoskeletal pain (back pain, arthralgia, bone pain; 15–25%)
- Hot flushes (vasomotor symptoms; 10–20%)
- Elevated liver transaminases (ALT, AST, ALP elevations; 10–15%)
Common
- Headache
- Anorexia (decreased appetite)
- Vomiting
- Diarrhea or constipation
- Rash and pruritus (skin rash and itching)
- Peripheral edema (swelling in hands, feet, or ankles)
- Urinary tract infections
- Cough and dyspnea (shortness of breath)
- Elevated bilirubin
- Weight gain
Uncommon
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
- Hepatobiliary disorders (hepatitis, elevated gamma-GT)
- Vaginal hemorrhage (breakthrough bleeding)
- Hypersensitivity reactions (urticaria, angioedema)
- Myalgia (muscle pain beyond general musculoskeletal complaints)
Rare
- Anaphylaxis (severe systemic allergic reaction)
- Hepatic failure (extremely rare, reported in post-marketing surveillance)
- Severe injection site reactions (sterile abscess, sciatic nerve injury – with improper technique)
Injection site reactions are one of the most characteristic side effects of fulvestrant and are directly related to the intramuscular administration route. Patients commonly experience localized pain during and after injection, which may be accompanied by transient induration (hardening), erythema (redness), or swelling at the injection site. These reactions are generally mild, self-limiting, and resolve within a few days. Applying warm compresses to the injection site, gentle massage after injection, and allowing the medication to reach room temperature before administration can help minimize discomfort.
Liver enzyme elevations occur in a meaningful proportion of patients and are typically mild (Grade 1–2) and asymptomatic. Periodic monitoring of liver function tests (ALT, AST, ALP, bilirubin) is recommended, particularly during the first several months of treatment. If significant elevations are detected (Grade 3 or higher, or clinical symptoms of hepatotoxicity), treatment interruption or discontinuation may be necessary. When fulvestrant is combined with CDK4/6 inhibitors, the liver monitoring requirements of the CDK4/6 inhibitor should also be followed, as some of these agents have additional hepatotoxic potential.
- Sudden onset of leg swelling, pain, or warmth (possible deep vein thrombosis)
- Sudden shortness of breath, chest pain, or coughing up blood (possible pulmonary embolism)
- Yellowing of the skin or eyes, dark urine, or severe abdominal pain (possible hepatic injury)
- Severe allergic reaction: difficulty breathing, facial/throat swelling, severe rash (anaphylaxis)
- Persistent severe injection site pain, redness, or drainage (possible abscess)
How Should You Store Fulvestrant Reddy?
Fulvestrant Reddy pre-filled syringes must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). The syringes should be kept in the original carton to protect from light exposure, as fulvestrant is sensitive to photodegradation. It is critical that the medication is not frozen, as freezing may affect the stability and uniformity of the solution, potentially compromising its efficacy and safety. If a syringe has been accidentally frozen, it should be discarded and not used.
For temporary storage outside the refrigerator (for example, during transport to the clinic or in the healthcare setting before administration), Fulvestrant Reddy may be stored at a temperature below 30°C (86°F) for a maximum of 28 days. The syringes should be returned to the refrigerator if not used within this period, provided the total time outside the refrigerator does not exceed 28 days. After the 28-day period at room temperature, the product should not be re-refrigerated and must be discarded.
Before administration, remove the pre-filled syringes from the refrigerator and allow them to reach room temperature naturally (approximately 15–30 minutes). Do not use any external heat sources such as microwave ovens or hot water to warm the syringes, as this may damage the medication. Visually inspect the solution before use: it should be a clear, colorless to yellow, viscous solution. Do not use the product if it appears cloudy, contains particulate matter, or if the syringe appears damaged.
Keep Fulvestrant Reddy out of the sight and reach of children. Do not use the medication after the expiry date stated on the carton and syringe label. The expiry date refers to the last day of the stated month. Any unused product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste, particularly as it is a cytotoxic-adjacent endocrine therapy.
What Does Fulvestrant Reddy Contain?
The active substance in Fulvestrant Reddy is fulvestrant. Each pre-filled syringe contains 250 mg of fulvestrant in 5 mL of solution (50 mg/mL concentration). A complete dose of 500 mg requires two pre-filled syringes. Fulvestrant is a steroidal compound with the chemical name 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5-(10)-triene-3,17-beta-diol. Its molecular formula is C32H47F5O3S, with a molecular weight of 606.77 g/mol.
The excipients (inactive ingredients) in the formulation serve important roles in ensuring drug stability, solubility, and proper delivery:
- Ethanol (96%): Acts as a co-solvent to maintain fulvestrant in solution. The ethanol content per 5 mL syringe is approximately 10% w/v. This small amount of alcohol is not expected to have clinical effects.
- Benzyl alcohol: Serves as a preservative and co-solvent. Each 5 mL syringe contains approximately 500 mg of benzyl alcohol (100 mg/mL). Although generally well-tolerated in adults, benzyl alcohol has been associated with serious adverse effects in neonates (“gasping syndrome”), which is not relevant to the indicated adult patient population.
- Benzyl benzoate: A solubilizing agent that helps maintain the fulvestrant in a homogeneous solution within the castor oil vehicle.
- Castor oil (refined): The primary vehicle for the intramuscular depot formulation. Castor oil provides the viscous medium that allows slow absorption of fulvestrant from the injection site, contributing to the drug's long duration of action and extended half-life. Patients with known allergies to castor oil should inform their healthcare provider.
Fulvestrant Reddy is presented as a clear, colorless to yellow, viscous solution in a 5 mL pre-filled glass syringe with a polystyrene plunger rod and a safety needle. Each carton contains two pre-filled syringes with safety needles (one complete dose). The syringe is equipped with a passive needle guard that automatically covers the needle after injection to prevent needlestick injuries.
Frequently Asked Questions
Fulvestrant Reddy and Faslodex both contain the same active substance (fulvestrant) at the same concentration (250 mg/5 mL) and are administered the same way (intramuscular injection). Fulvestrant Reddy is a generic version manufactured by Dr. Reddy's Laboratories, while Faslodex is the original brand-name product developed by AstraZeneca. Bioequivalence studies have demonstrated that Fulvestrant Reddy provides the same drug exposure and therapeutic effect as Faslodex. The primary difference is typically in cost, with generic versions generally being more affordable, improving patient access to this important breast cancer treatment.
No, Fulvestrant Reddy must be administered by a trained healthcare professional. Unlike some other injectable cancer treatments that allow self-administration (such as subcutaneous injections), fulvestrant requires intramuscular injection into the gluteal muscles (buttocks), which is not practical for self-injection. The injections should be given at your oncology clinic, hospital, or by a home-care nurse with appropriate training. Each visit involves two injections (one in each buttock), each administered slowly over 1–2 minutes.
Treatment with Fulvestrant Reddy should continue for as long as it is providing clinical benefit and is well-tolerated. In metastatic breast cancer, treatment is typically continued until disease progression is confirmed on imaging (CT scans, bone scans, or other appropriate modalities), or until unacceptable toxicity occurs. Your oncologist will schedule regular assessments (typically every 3–4 months) to evaluate treatment response and determine whether fulvestrant should be continued, the combination partner changed, or treatment switched to a different line of therapy. Some patients may remain on fulvestrant-based therapy for many months to years if the disease remains controlled.
Hair loss (alopecia) is not a common side effect of fulvestrant when used as monotherapy. Unlike chemotherapy drugs that target rapidly dividing cells, fulvestrant is an endocrine therapy that specifically targets estrogen receptors and does not directly damage hair follicles. Some patients may experience mild hair thinning, which is generally much less severe than chemotherapy-induced alopecia. However, when fulvestrant is combined with CDK4/6 inhibitors, particularly abemaciclib, the risk of alopecia may be slightly increased. If you notice significant hair changes, discuss this with your oncologist.
Yes, fulvestrant can be used as first-line endocrine therapy for HR+/HER2– advanced or metastatic breast cancer. The FALCON trial demonstrated that fulvestrant 500 mg was superior to the aromatase inhibitor anastrozole as first-line monotherapy in postmenopausal women with HR+ advanced breast cancer who had not received prior endocrine therapy (median PFS: 16.6 months vs. 13.8 months; HR 0.80, p = 0.0486). More commonly, fulvestrant is used in the first-line setting in combination with a CDK4/6 inhibitor, as this approach has shown significant survival benefits in multiple clinical trials. Your oncologist will determine the optimal treatment strategy based on your individual circumstances.
Mild to moderate injection site discomfort is common and usually resolves within a few days. To reduce discomfort, the medication should be warmed to room temperature before injection, the injection should be given slowly (over 1–2 minutes), and gentle pressure or warm compresses can be applied afterward. However, if you experience severe or persistent pain, increasing redness, warmth, swelling, or any drainage from the injection site, contact your healthcare provider promptly as this may indicate a local reaction requiring treatment. Alternating injection sites (left and right buttock) and slight variations in the exact injection location can also help minimize cumulative irritation.
References
- European Medicines Agency (EMA). Fulvestrant – Summary of Product Characteristics. Last updated 2025. Available at: EMA Fulvestrant.
- U.S. Food and Drug Administration (FDA). Faslodex (fulvestrant) – Prescribing Information. AstraZeneca Pharmaceuticals. Revised 2024.
- Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–4600. doi:10.1200/JCO.2010.28.8415.
- Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005. doi:10.1016/S0140-6736(16)32389-3.
- Turner NC, Ro J, André F, et al. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer (PALOMA-3). N Engl J Med. 2015;373(3):209–219. doi:10.1056/NEJMoa1505270.
- Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (MONALEESA-3). N Engl J Med. 2020;382(6):514–524. doi:10.1056/NEJMoa1911149.
- Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy (MONARCH 2). JAMA Oncol. 2020;6(1):116–124. doi:10.1001/jamaoncol.2019.4782.
- Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649. doi:10.1016/j.annonc.2020.09.010.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2025.
- British National Formulary (BNF). Fulvestrant. National Institute for Health and Care Excellence (NICE). 2025.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in medical oncology, breast cancer, endocrine therapy, and clinical pharmacology with extensive experience in the management of hormone receptor-positive breast cancer.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, ESMO, ASCO, NCCN).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.